Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Marion Loirat
Observed names:
M Loirat,
M. Loirat
Institution:
Centre Hospitalier Saint-Nazaire
Observed institutions:
Centre Hospitalier Universitaire de Nantes,
Centre d'Investigation Clinique de Nantes,
Centre Hospitalier Saint-Nazaire,
Nantes Université
ORCID:
0000-0002-0171-9389
Observed ORCID:
0000-0002-0171-9389
OpenAlex ID:
A5043743398
Autologous Stem Cell Transplantation: An Effective Salvage Therapy in Multiple Myeloma
2012
·
Emilie Lemieux
, Cyrille Hulin
, et al.
·
Transplantation and Cellular Therapy
·
72
Azacitidine salvage therapy for relapse of myeloid malignancies following allogeneic hematopoietic SCT
2014
·
B Tessoulin
, J Delaunay
, et al.
·
Bone Marrow Transplantation
·
58
Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide
2017
·
Laurence Lodé
, Audrey Ménard
, et al.
·
Haematologica
·
54
PDF
Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center study
2015
·
A. Lassalle
, P. Thomaré
, et al.
·
Annals of Oncology
·
51
Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center
2014
·
M. Loirat
, P. Chevallier
, et al.
·
Annals of Oncology
·
45
Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
2022
·
Vincent Marmouset
, Justine Decroocq
, et al.
·
Clinical Cancer Research
·
33
PDF
Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM
2024
·
Florent Malard
, Arthur Bobin
, et al.
·
Blood Cancer Journal
·
30
PDF
Comparison of Outcomes after Two Standards-of-Care Reduced-Intensity Conditioning Regimens and Two Different Graft Sources for Allogeneic Stem Cell Transplantation in Adults with Hematologic Diseases: A Single-Center Analysis
2013
·
Amandine Le Bourgeois
, Catherine Mohr
, et al.
·
Transplantation and Cellular Therapy
·
22
PDF
Autologous stem-cell collection following VTD or VRD induction therapy in multiple myeloma: a single-center experience
2020
·
Vanille Laurent
, Clémentine Fronteau
, et al.
·
Bone Marrow Transplantation
·
15
Effect of graft source on mismatched unrelated donor hemopoietic stem cell transplantation after reduced intensity conditioning
2013
·
F Malard
, S Fürst
, et al.
·
Leukemia
·
14
Late Relapse after Allogeneic Stem Cell Transplantation in Patients Treated for Acute Myeloid Leukemia: Relapse Incidence, Characteristics, Role of Conditioning Regimen, and Outcome
2024
·
Chloé Antier
, Maxime Jullien
, et al.
·
Cancers
·
12
PDF
Diagnosis and prognosis are supported by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study
2020
·
Sophie Vantyghem
, Pierre Peterlin
, et al.
·
Haematologica
·
12
PDF
Efficacy of lenalidomide plus dexamethasone in patients older than 75 years with relapsed multiple myeloma
2012
·
Cyrille Touzeau
, Nicolas Blin
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
·
12
CD200 expression in flow cytometry helps to distinguish mantle cell lymphoma from other CD 5‐positive B ‐cell neoplasms
2018
·
Camille Debord
, Nelly Robillard
, et al.
·
Hematological Oncology
·
9
GPVI as a Potential New Biomarker for Myelofibrosis Diagnosis
2025
·
Xavier Hittinger
, Yannick Le Bris
, et al.
·
American Journal of Hematology
·
2
Durable Responses With Front‐Line Rituximab in Autoimmune Cytopenias Associated With Indolent B‐Cell Clones
2025
·
Yoann Zadro
, Amélie Lusque
, et al.
·
American Journal of Hematology
·
1
PDF
Upfront Allogeneic-Stem Cell Transplantation for Patients with Non-Localized Untreated Peripheral T-Cell Lymphoma: An Intention-to-Treat Analysis from a Single Center
2014
·
Marion Loirat
, Patrice Chevalier
, et al.
·
Blood
·
1
Backtracking Subclonal Mutations Of TP53 In Myelodysplasia (MDS) With Del(5q) With Next-Generation Sequencing (NGS)
2013
·
Laurence Lodé
, Audrey Ménard
, et al.
·
Blood
·
1
Supplementary Figure 2 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
2025
·
Vincent Marmouset
, Justine Decroocq
, et al.
Supplementary Figure 3 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
2025
·
Vincent Marmouset
, Justine Decroocq
, et al.
Supplementary Table 1 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
2025
·
Vincent Marmouset
, Justine Decroocq
, et al.
Supplementary Table 4 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
2025
·
Vincent Marmouset
, Justine Decroocq
, et al.
Supplementary Table 3 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
2025
·
Vincent Marmouset
, Justine Decroocq
, et al.
Supplementary Table 2 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
2025
·
Vincent Marmouset
, Justine Decroocq
, et al.
Supplementary Figure 1 from Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
2025
·
Vincent Marmouset
, Justine Decroocq
, et al.
Show more works
View as search
Works count:
45
Citation count:
444
H-index:
12
I10-index:
13
Year
Topic
Type
